Synergy rockets on Phase III constipation data
This article was originally published in Scrip
Executive Summary
Positive topline results from the first of two pivotal Phase III trials of Synergy Pharmaceuticals' chronic idiopathic constipation drug plecanatide have sent the company's share price soaring.
You may also be interested in...
Synergy Flaunts Constipation Data From Linzess Challenger
Synergy Pharmaceuticals, which is waiting on a decision from the US FDA on its constipation drug plecanatide, provided additional data from two pivotal Phase III trials at Digestive Disease Week (DDW) in San Diego recently. The product will go up against Linzess, which is marketed by Allergan and Ironwood Pharmaceuticals, and is expected to compete on its better side effect profile.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.